DaVita HealthCare Partners (NYSE: DVA) is one of 50 publicly-traded companies in the “Healthcare Facilities & Services” industry, but how does it weigh in compared to its rivals? We will compare DaVita HealthCare Partners to similar companies based on the strength of its earnings, risk, profitability, analyst recommendations, dividends, valuation and institutional ownership.
Institutional and Insider Ownership
83.2% of DaVita HealthCare Partners shares are owned by institutional investors. Comparatively, 69.7% of shares of all “Healthcare Facilities & Services” companies are owned by institutional investors. 2.1% of DaVita HealthCare Partners shares are owned by insiders. Comparatively, 15.4% of shares of all “Healthcare Facilities & Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares DaVita HealthCare Partners and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|DaVita HealthCare Partners||$15.01 billion||$2.45 billion||9.13|
|DaVita HealthCare Partners Competitors||$5.43 billion||$855.44 million||37.30|
DaVita HealthCare Partners has higher revenue and earnings than its rivals. DaVita HealthCare Partners is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
DaVita HealthCare Partners has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, DaVita HealthCare Partners’ rivals have a beta of 1.01, indicating that their average stock price is 1% more volatile than the S&P 500.
This table compares DaVita HealthCare Partners and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|DaVita HealthCare Partners||8.68%||14.02%||3.78%|
|DaVita HealthCare Partners Competitors||6.86%||0.47%||0.55%|
This is a summary of recent recommendations and price targets for DaVita HealthCare Partners and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|DaVita HealthCare Partners||2||6||1||0||1.89|
|DaVita HealthCare Partners Competitors||190||1293||1828||32||2.51|
DaVita HealthCare Partners presently has a consensus price target of $65.00, indicating a potential upside of 9.52%. As a group, “Healthcare Facilities & Services” companies have a potential downside of 5.29%. Given DaVita HealthCare Partners’ higher possible upside, equities research analysts plainly believe DaVita HealthCare Partners is more favorable than its rivals.
DaVita HealthCare Partners beats its rivals on 7 of the 13 factors compared.
DaVita HealthCare Partners Company Profile
DaVita Inc., formerly DaVita HealthCare Partners Inc., operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. Its DMG division is a patient- and physician-focused integrated healthcare delivery and management company that provides medical services to members through capitation contracts. Its segments include U.S. dialysis and related lab services, DMG, and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2016, it had operated or provided administrative services to 154 outpatient dialysis centers.
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.